Oslo-listed BerGenBio, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, has appointed Olav Hellebø as CEO. He replaces Martin Olin who joined the…
Oslo-listed BerGenBio, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, has appointed Olav Hellebø as CEO. He replaces Martin Olin who joined the…
…
…